| 1351 |
Cancer Biother Radiopharm, 14, 139, 99 - Mol Immunol, 36, 789, 99 - Cancer Immunol Immunother, 43, 26, 96 - Hum Antibodies Hybridomas, 6, 57, 95 (chimeric) - Cancer Res, 47, 830, 87 - Hybridoma, 5, 265, 86 - US Patent 6783936 (peptide epitopes) - US Patent 6696276 - US Patent 6403096 - US Patent 6274343 - US Patent 6217871 (epitopes) - US Patent 5194594 - US Patent 5053394 (American Cyanamid Co., US) - US Patent 4724213 - PCT Patent Application 00/24777 |
Blood, 113, 4903, 09 - Mol Cancer, 8, 25, 09 - Bioconj Chem, 18, 912, 07 - Int J Oncol, 31, 729, 07 - Leuk Lymphoma, 48, 944, 07 (chimeric) - Blood, 109, 4980, 07 - J Nucl Med, 48, 1338, 07 - Cancer Biother Radiopharm, 22, 342 and 521 and 531, 07 - Clin Cancer Res, 13, 5621s, 07 - Cancer Immunol Immunother, 55, 1451, 06 - Clin Cancer Res, 11, 7075s, 05 - Cancer Biother Radiopharm, 19, 545, 04 - J Natl Cancer Inst, 95, 741, 03 - Blood, 101, 3641, 03 - Cancer Biother Radiopharm, 18, 231, 03 - J Nucl Med, 44, 1322, 03 - Cancer Immunol Immunother, 52, 309, 03 - Cancer Immunol Immunother, 52, 309, 03 - Br J Cancer, 85, 463, 01 - Cancer Biother Radiopharm, 16, 213, 01 - Clin Lymphoma, 1, 112, 00 - J Leukoc Biol, 68, 662, 00 - Anticancer Res, 20, 3647, 00 - Cancer Radiother Biopharm, 14, 167, 99 - Clin Cancer Res, 5, 533, 99 - Br J Cancer, 80, 331, 99 - J Nucl Med, 40, 1317 and 2014, 99 - J Nucl Med, 39, 667, 98 - Anticancer Res, 18, 2779, 98 - Clin Cancer Res, 3, 1253, 97 - Clin Cancer Res, 3, 71, 97 - Cancer, 80, suppl 12, 2706, 97 - Cancer Biother Biopharm, 11, 203, 96 - Cancer Res, 56, 4998, 96 - Blood, 87, 5171, 96 - Blood, 87, 3803, 96 - Int J Biol Markers, 10, 67, 95 - J Immunother Emph Tumor Immunol, 18, 221, 95 - Cancer, 73, 1425, 94 - Cancer Biother, 8, 3, 93 - J Nucl Med, 31, 473, 90 - J Nucl Med, 31, 1059, 90 - Cancer Res, 50, 2991, 90 - Hematol Oncol, 7, 155, 89 - J Nucl Med, 29, 217, 88 - Int J Cancer, suppl 3, 96, 88 - Int J Biol Markers, 2, 49, 87 - J Nucl Med, 27, 1243, 86 |